Metrics

  • citations in SCIndeks: [1]
  • citations in CrossRef:0
  • citations in Google Scholar:[]
  • visits in previous 30 days:62
  • full-text downloads in 30 days:51

Contents

article: 8 from 65  
Back back to result list
2018, vol. 40, iss. 2, pp. 73-85
Benzodiazepine (ab)use and addictive potential: Analyses of consumption in Serbia for the period 2014-2016
aUniversity of Belgrade, Faculty of Medicine, Institute of Pharmacology
bUniversity of Belgrade, Faculty of Medicine
cUniversity of Belgrade, Faculty of Medicine + University of Belgrade, Faculty of Medicine, Institute of Neurology and Psychiatry for Children and Youth
dUniversity of Belgrade, Faculty of Medicine + Clinical Center of Serbia, Clinic for Psychiatry, Belgrade

emailjanko.samardzic@med.bg.ac.rs
Keywords: benzodiazepines; consumption; abuse; addictive potential
Abstract
Benzodiazepines, as substances of abuse or recreational drugs, have largely suppressed the use of barbiturates, methaqualone and glutethimide. The advantage of benzodiazepines, used for medical use or abuse, compared with older drugs is certainly a safer profile and lower risk of serious toxic effects after overdose. Benzodiazepines are much safer drugs in the case of overdose compared with barbiturates, however they also have a number of side effects, including the development of tolerance and dependence. Short-term benzodiazepines, such as lorazepam, bromazepam and alprazolam, have the greatest addictive potential and they are the most commonly used anxiolytics in our population. The benzodiazepine consumption analysis in our country points to possible irrational prescribing and abuse. Benzodiazepines research and analysis of the consequences of their long-term use are aimed on changing patients' attitude, education, and raising awareness of better control of prescribing these medicines by healthcare professionals. In recent years an intensive research has been carried out to discover selective anxiolytic agents that will provide the same or similar efficacy and tolerability with less side effects.
References
Balon, R., Chouinard, G., Cosci, F., Dubovsky, Steven L., Fava, Giovanni A., Freire, Rafael C., Greenblatt, David J., Krystal, John H., Nardi, Antonio E., Rickels, K., Roth, T., Salzman, C., Shader, R., Silberman, Edward K., So (2018) International Task Force on Benzodiazepines. Psychotherapy and Psychosomatics, 87(4): 193-194
Dell'osso, B., Lader, M. (2013) Do benzodiazepines still deserve a major role in the treatment of psychiatric disorders? A critical reappraisal. European Psychiatry, 28(1): 7-20
Dimitrijević, I. (2015) Bolesti zavisnosti, dijagnostika, lečenje, prevencija. Beograd: Medicinski fakultet
Institut za javno zdravlje Srbije 'Dr Milan Jovanović Batut' (2014) Nacionalno istraživanje o stilovia života stanovništva srbije
Kafeel, H., Rukh, R., Iqbal, J., Naveed, S. (2014) Irrational dispensing and self medication of benzodiazepines by general population of a big city. Journal of Pharmaceutical & Scientific Innovation, 3(2): 178-181
Kurko, T., Saastamoinen, L.K., Tuulio-Henriksson, A., Taiminen, T., Tiihonen, J., Airaksinen, M., Hietala, J. (2018) Trends in the long-term use of benzodiazepine anxiolytics and hypnotics: A national register study for 2006 to 2014. Pharmacoepidemiology and Drug Safety, 27(6): 674-682
Lader, M. (2011) Benzodiazepines revisited-will we ever learn?. Addiction, 106(12): 2086-2109
Madruga, C.S., Paim, T.L., Palhares, H.N., Miguel, A.C., Massaro, L.T.S., Caetano, R., Laranjeira, R.R. (2018) Prevalence of and pathways to benzodiazepine use in Brazil: the role of depression, sleep, and sedentary lifestyle. Brazilian Journal of Psychiatry, 41(1): 44-50
Manubay, J.M., Muchow, C., Sullivan, M.A. (2011) Prescription Drug Abuse: Epidemiology, Regulatory Issues, Chronic Pain Management with Narcotic Analgesics. Primary Care: Clinics in Office Practice, 38(1): 71-90
National Institute on Drug Abuse (NIH) Medline plus: Prescription drug abuse. www.nlm.nih.gov/medlineplus/prescriptiondrugabuse.html
Novak, S.P., Håkansson, A., Martinez-Raga, J., Reimer, J., Krotki, K., Varughese, S. (2016) Nonmedical use of prescription drugs in the European Union. BMC Psychiatry, 16(1)
Olfson, M., King, M., Schoenbaum, M. (2015) Benzodiazepine Use in the United States. JAMA Psychiatry, 72(2): 136
Preston, J.D., o'neal J.H., Talaga, M.C. (2013) Handbook of clinical psychopharmacology for therapists. Oakville, Canada: New Harbinger Publications Inc, 7th Edition
Samardzic, J., Svob, S.D. (2016) Benzodiazepines and Anxiety Disorders: From Laboratory to Clinic. in: Durbano Federico, Marchesi Barbara [ed.] New Developments in Anxiety Disorders, IntechOpen
Stojkov, S., Đurić, D., Milovanović, S., Mitrović, M., Radonjić, V. (2015) Characteristics of psycholeptic and psychoanaleptic medicine use in general population in Subotica for the period 2009/2012. Engrami, vol. 37, br. 4, str. 65-78
Šoškić, M., Dabanović, V., Čukić, A., Mugoša, S. (2016) Benzodiazepine use in general population, the municipality of Berane, Montenegro. Racionalna terapija, vol. 8, br. 2, str. 9-14
Vinkers, C.H., Olivier, B. (2012) Mechanisms Underlying Tolerance after Long-Term Benzodiazepine Use: A Future for Subtype-Selective Receptor Modulators?. Advances in Pharmacological Sciences, 2012: 1-19
Xu, W., Chen, Y., Zhao, Y., Wang, L., Li, J., Liu, C. (2018) A Clinical Study of Toxication Caused by Carbamazepine Abuse in Adolescents. BioMed Research International, 1-6
 

About

article language: Serbian
document type: Actual Topics
DOI: 10.5937/Engrami1802073S
published in SCIndeks: 28/02/2019